Stockscreener 앱 받기
161.87
0.22%
-0.35
시간 외 거래:
161.79
-0.08
-0.05%
전일 마감가:
$162.22
열려 있는:
$163.44
하루 거래량:
704.26K
Relative Volume:
0.73
시가총액:
$8.48B
수익:
$708.24M
순이익/손실:
$-188.30M
주가수익비율:
-43.29
EPS:
-3.7392
순현금흐름:
$-70.99M
1주 성능:
-4.83%
1개월 성능:
-20.68%
6개월 성능:
-12.11%
1년 성능:
+24.92%
1일 변동 폭
$160.27
$169.96
1주일 범위
$155.18
$170.80
52주 변동 폭
$120.12
$260.19
Axsome Therapeutics Inc Stock (AXSM) Company Profile
명칭
Axsome Therapeutics Inc
전화
(212) 332-3241
주소
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
161.87 | 8.48B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-23 | 재개 | Truist | Buy |
| 2026-07-21 | 개시 | BMO Capital Markets | Outperform |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | 개시 | B. Riley Securities | Buy |
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 개시 | Oppenheimer | Outperform |
| 2025-04-07 | 개시 | Jefferies | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-31 | 재확인 | Mizuho | Outperform |
| 2024-09-03 | 개시 | Wells Fargo | Overweight |
| 2024-08-06 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-04-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2024-01-25 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-08-08 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 개시 | Piper Sandler | Neutral |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2022-09-07 | 재개 | Mizuho | Buy |
| 2021-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 개시 | Berenberg | Buy |
| 2021-01-08 | 개시 | Jefferies | Buy |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-09-29 | 개시 | BofA Securities | Underperform |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-14 | 개시 | Cowen | Outperform |
| 2019-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-16 | 재확인 | Guggenheim | Buy |
| 2019-10-16 | 개시 | Guggenheim | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-28 | 개시 | SunTrust | Buy |
| 2019-05-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-08 | 개시 | SVB Leerink | Outperform |
| 2019-03-15 | 재확인 | H.C. Wainwright | Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2015-12-15 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
RBC Capital reiterates Axsome Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada
Why Axsome Therapeutics shares are falling today - Quiver Quantitative
Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For? - Yahoo Finance
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? - Zacks Investment Research
Axsome Therapeutics, Inc. (19X.F) Stock Price, News, Quote & History - Yahoo Finance
Enterprise value to EBIT forward of Axsome Therapeutics, Inc. – DUS:19X - TradingView
Axsome Therapeutics Stock: 12 Straight Red Days, Down 15% - Trefis
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - The Globe and Mail
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - The Globe and Mail
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - Yahoo Finance
Where Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's? - The Motley Fool
Tangible book value per share of Axsome Therapeutics, Inc. – HAN:19X - TradingView
Axsome Therapeutics (AXSM) Gets a Buy from Bank of America Securities - The Globe and Mail
Axsome Therapeutics Stock Extends An 11-Day Losing Streak To A 14% Loss - Trefis
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $290 - Moomoo
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research
10 Red Days In A Row: Axsome Therapeutics Stock Is Down 13% - Trefis
Axsome Therapeutics on Pace for Longest Losing Streak Since December 2018 -- Data Talk - Moomoo
Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $295.00 by Analysts at Royal Bank Of Canada - MarketBeat
Axsome Therapeutics Is Maintained at Outperform by RBC Capital - Moomoo
Axsome Therapeutics Stock Slides 12% Over 9 Straight Down Days - Trefis
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? - The Motley Fool
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026? - Yahoo Finance
Before markets open Nov. 2, Axsome will report results and host an 8 a.m. call. - Stock Titan
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2 - GlobeNewswire
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting - Lelezard
Why Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM) - Yahoo Finance
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? - Yahoo Finance
AXSOME THERAPEUTICS, INC. : DEUTSCHE BANK CUTS TARGET PRICE TO $267 FROM $280 - webull.com
EBITDA per share of Axsome Therapeutics, Inc. – HAN:19X - tradingview.com
Axsome Therapeutics options flow shows heavy put skew ahead of binary catalyst - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.4% on Analyst Downgrade - MarketBeat
Axsome Therapeutics slides as investors weigh launch execution and policy risks - Quiver Quantitative
Axsome Therapeutics, Inc. Revenue Breakdown – HAN:19X - tradingview.com
Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $267.00 by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Axsome Therapeutics Is Maintained at Buy by Deutsche Bank - Moomoo
Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating - marketscreener.com
Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating - Yahoo Finance
Axsome Therapeutics (NasdaqGM:AXSM) Stock Forecast & Analyst Predictions - Simply Wall Street
Axsome Therapeutics Is Maintained at Equal-Weight by Morgan Stanley - Moomoo
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Hold Rating, Maintains Target Price $251 - Moomoo
AXSOME THERAPEUTICS, INC. : TRUIST SECURITIES ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $285 VS $200 - webull.com
$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today - Benzinga
Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating - marketscreener.com
Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating - Yahoo Finance
Axsome Therapeutics Announces Results of the Shared Goals - globenewswire.com
Is Axsome Therapeutics’ (AXSM) New CNS Data Enough To Reinforce Its Neuropsychiatric Portfolio Story? - Yahoo Finance
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference - Yahoo Finance
Axsome Therapeutics (AXSM) Stock Looks Undervalued As Its 5 Year 7x Run Continues - Yahoo Finance
Axsome Therapeutics Inc (AXSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Axsome Therapeutics Inc 주식 (AXSM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
Sep 03 '26 |
Sale |
208.65 |
10,000 |
2,086,500 |
0 |
| Mark Jacobson | Officer |
Sep 03 '26 |
Proposed Sale |
208.35 |
10,000 |
2,083,500 |
0 |
| Herriot Tabuteau | Officer |
Aug 06 '26 |
Proposed Sale |
210.13 |
4,660 |
979,206 |
0 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 06 '26 |
Sale |
213.95 |
4,660 |
997,007 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 06 '26 |
Option Exercise |
4.95 |
4,660 |
23,067 |
11,889 |
| Herriot Tabuteau | Officer |
Aug 05 '26 |
Proposed Sale |
212.85 |
45,004 |
9,579,101 |
0 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 05 '26 |
Option Exercise |
4.95 |
45,004 |
222,770 |
52,233 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Aug 05 '26 |
Sale |
212.01 |
45,004 |
9,541,298 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Jul 01 '26 |
Sale |
240.25 |
49,666 |
11,932,256 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Jul 01 '26 |
Option Exercise |
4.95 |
49,666 |
245,847 |
56,895 |
2.96%
자본화:
|
볼륨(24시간):